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Abstract
Objectives—Cervical cancer is increasing but underestimated in developing countries. We 
calculated the observed and expected incidence of cervical cancer in Lusaka and Southern and 
Western provinces of Zambia.
Methods/Materials—Data for 2007-2012 was obtained for the 3 provinces. Data included age, 
residence, year of diagnosis, marital status, occupation, HIV, stage, radiotherapy and 
chemotherapy. Expected incidence in Southern and Western provinces was calculated based on 
observed incidence for Lusaka province, adjusting for HIV.
Results—Crude and age-standardized incidence rates (ASR) in Lusaka were 2-4 times higher 
than incidence in the other 2 provinces. Lusaka had a rate of 54.1/105 and ASR of 82.1/105 in the 
age group 15-49. The Southern province had a rate of 17.1/105 and ASR of 25.5/105; Western 
province rate of 12.3/105 and ASR rate of 17.2/105. The observed cervical cancer incidence rates 
in the Southern and Western provinces were lower than the rate in Lusaka, possibly due to the 
uncertainty of underreporting/under-diagnosis or actual lower risk for reasons yet unclear. HIV 
seroprevalence rate in patients from the 3 provinces were 46 – 93% higher than seroprevalence in 
the respective general populations.
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Conclusion—Cervical cancer is significantly underestimated in Zambia and HIV has a 
significant role in pathogenesis. Future studies should establish methods for case ascertainment 
and better utilization of hospital- and population-based registries in Zambia and other similar 
developing countries.
Keywords
Zambia; cervical cancer; incidence; developing countries (LMICs)
INTRODUCTION
Cervical cancer has consistently been among the top 4 most common cancers in women 
worldwide (1-3). In 2012, there were an estimated 528,000 new cases and 266,000 deaths 
worldwide (1). Eighty-three percent of all incident cases and 85% of mortality occurs in 
low-and middle-income countries (LMICs) (1,4,5).
Cervical cancer is the most common cancer and cause of cancer-related death in women in 
sub-Saharan Africa. It is quite likely that the disease burden in sub-Saharan Africa is 
underestimated due to the aforementioned reasons in addition to poor cancer registration (5).
In Zambia, the National Cancer Registry (NCR) has been poorly funded and understaffed, 
adding to limited efficiency of cancer registration. In 2008, the NCR was estimated to 
capture approximately 10 – 15 % of cancers countrywide (6).
The International Agency for Research on Cancer (IARC) estimates age-standardized 
incidence rate of cervical cancer in Zambia at 58.0 per 105 and mortality at 36.2 per 105 , 
making cervical cancer the most common cause of cancer morbidity and mortality in 
women, and overall in Zambia (1,7). Studies have shown that among the leading factors for 
cervical cancer in Zambia include the high prevalence of Human Papilloma Virus (HPV) 
types 16 and 18 (21.6% each), and the high national adult HIV prevalence of 16% (23% in 
Lusaka) (6-11). Before the Center for Infectious Disease Research in Zambia (CIDRZ) 
introduced a cervical cancer screening program using visual inspection with acetic acid 
(VIA) in 2006, there was no screening for cervical cancer in Zambia and all screening was 
opportunistic (11). Over the course of 7 years (2006 – 2013), the CIDRZ screening program 
has provided screening to over 100, 000 women (11) and established 24 screening sites — 
12 in Lusaka province, and at least 1 in every provincial headquarters (Southern province = 
3, Western province =1).
By regulation, all health facilities in Zambia are required to report disease cases to the 
Ministry of Health (MoH). However, compliance from private hospitals and clinics is poor 
as very often statistics from private hospitals are conspicuously absent from official 
statistical health bulletins and reports (12). In late 2006, a new cancer hospital, the Cancer 
Diseases Hospital (CDH), was opened in Lusaka, for radiotherapy and chemotherapy 
treatment. Other health facilities in Zambia may diagnose cervical cancer but in order for 
patients to receive radiotherapy treatment they must be managed at the CDH. Therefore, we 
conducted this study to calculate incidence of cervical cancer in Lusaka province by pooling 
data from the main diagnostic and treatment referral sites. The study also aimed to utilize the 
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findings from Lusaka, the region with the best diagnostic and treatment facilities in Zambia, 
to predict the incidence in the limited-resource settings of Southern and Western provinces. 
Out of the approximately 13 million individuals and 9 provinces of Zambia, Lusaka 
province has the largest population of about 2 million individuals and population density100 
per square kilometer (13). The province is also the most economically developed with a 
relative low poverty prevalence of 24% (19). The Southern province is in the middle 
category with approximately 1.5 million individuals, a density of 19 per square kilometer, 
and a poverty prevalence of 67% (13, 19). The Western province is one of the two poorest 
provinces and has an approximate population of 900,000 individuals a population density 7 
per square kilometer, and a poverty prevalence of 80% (13, 19).
METHODS
Zambia is a country of 753,612 square kilometers geographic area and an estimated 
population of 13,718,722 in 2011 (13). The country is divided into 9 provincial regions and 
Lusaka province has the largest population at approximately 2,362,967 individuals, Southern 
province has a population of approximately 1,642,757 individuals, and Western province 
926,478 individuals (13).
Data sources
In Lusaka province we obtained data from the following sites: the Cancer Diseases Hospital 
(CDH, n = 987), the University Teaching Hospital Pathology laboratory (UTH, n = 490), the 
Prospects Hill Clinic Pathology laboratory (PHC, n = 48), and the National Cancer Registry 
(NCR, n = 1739). In Southern province, we obtained data from Livingstone General 
Hospital (LVG, n = 123). In Western province we obtained data from Lewanika General 
Hospital (LWG, n = 95) (Figure 1).
One of the co-authors of this paper (MK) led the data collection process at all research sites 
in collaboration with the local teams. Data was obtained data from electronic databases, 
patient medical records, and admission logbooks. The study included data from the Southern 
and Western provinces from 2007 to 2012, however for the Lusaka province, since the 
National Cancer Registry is one of the main sources of information from this province and 
its data was incomplete for 2012; we restricted data for the Lusaka province to the period 
with complete data from all study sources (2007-2011).
The CDH is a 3rd level hospital and the only center that provides radiotherapy and 
chemotherapy in Zambia. The UTH is the largest 3rd level hospital in Zambia and its 
Pathology laboratory receives tissue specimens for processing from all public health 
facilities in Zambia and some private facilities. Prospects Hill Clinic is a private pathology 
diagnostic laboratory that serves patients from Lusaka and receives tissue specimens for 
processing from the UTH and the Cervical Cancer Prevention Program in Zambia (CCPPZ). 
Livingstone General Hospital is the biggest 2nd level hospital in Southern province and 
serves part of Western province (Sesheke district) as well. Lewanika General Hospital used 
to be a 2nd level hospital to cover Western province but due to declining specialist doctor 
numbers and deteriorating infrastructure, the hospital is now a 1st level. However, Lewanika 
General Hospital still remains the largest referral point for patients in the Western province. 
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The NCR mainly covers Lusaka province; however, active collection of cases in other 
provinces is conducted depending on availability of resources.
Data variables
We collected the following patient information from all the sources: patient name, age, year 
of diagnosis, referral hospital, and province location. Marital status, HIV status, and stage at 
diagnosis were obtained mainly from the CDH and NCR. Occupation, histology, and 
radiotherapy and chemotherapy treatment information was only from the CDH. Data from 
Lewanika General Hospital and Livingstone General Hospital had sparse information on 
HIV status, marital status, occupation, and stage. This information was found in doctors’ 
clinical notes and side remarks on patient files and logbooks.
Data Management
We applied a strict criterion for removing duplicates and recurrences. The records didn't 
necessarily have to match exactly on patient name, age, year of diagnosis and location to be 
considered duplicate. Based on our knowledge of patient navigation, variations in spelling of 
names, and mismatches in data entry between different points observed under this study, we 
used our judgment to consider duplicates in some cases.
Data Analysis
We used the Central Statistical Office (CSO) 2010 Census of Population and Housing report 
data, and the CSO Population and Demographic Projections 2011 – 2035 report data for the 
population denominators 2010 – 2012. For the years 2007 – 2009 we applied the geometric 
population projection method based on the 2000 – 2010 provincial annual average 
population growth rates for the population denominators. The denominator used in all 
calculations was the female population.
The direct standardization method and the WHO 2000 – 2025 World Standard Population 
(14) was used to calculate age-standardized rates (ASR).
The Zambia Demographic and Healthy Survey 2007 reported HIV prevalence in the 
reproductive age 15 – 49 of 20.8% in Lusaka, 14.5% in Southern, and 15.2% in Western 
province (15). We applied direct proportion adjustment to calculate expected incidence rates 
in Southern and Western provinces based on observed Lusaka province incidence adjusting 
for respective provincial HIV prevalence.
T-tests were used to compare mean values between groups and Chi-squared test was used 
for comparison of proportions between groups. All tests were at 95% significance. SPSS 
21.0 was used to perform all statistical analyses.
The study was approved by the institutional review boards of the University of Nebraska 
and the Ministry of Health of Zambia.
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RESULTS
Figure 1 shows a summary of the collected data. At UTH Pathology laboratory, out of 2032 
suspected cervical cancer queries, 976 (48%) were histopathologically-confirmed cervical 
cancers and 1056 (52%) were non-cancers or missing results. Non-cancer specimens 
comprised cervical intraepithelial neoplasia (n = 364, 34.5%), cervicitis (n = 91, 8.6%), 
condyloma acuminata (n = 77, 7.3%), other infections (n = 249, 23.6%), normal (n = 160, 
15.2%), and missing (n = 115, 10.9%).
Table 1 shows demographic characteristics of patients seen at the study hospitals. The mean 
age at diagnosis was 46.3 ±15.04, 50 ± 14.96, and 49.1 ± 14.81 years for Lusaka, Southern, 
and Western province, respectively. We observed a significant difference between age of 
patients in the 3 provinces (p < 0.001), with patients from the Southern and Western 
provinces being older compared to Lusaka. Overall, between the 3 provinces about 72% of 
cervical cancer patients were married.
Table 2, illustrates the clinical characteristics of patients seen at the study hospitals with 
clinical data details missing for many cases, high proportion of advanced stages (stage ≥ II) 
among cases for whom clinical stage is known, and almost three-fourths of cases not 
receiving any treatment or their treatment status not known and a high proportion with 
histology proof (an exception in sub-Saharan Africa). In the Lusaka and Southern provinces, 
92.5 % of patients for whom clinical stage was known had advanced stage cervical cancer, 
and in the Western province the proportion was 94.5%. For patients whom histology was 
clearly indicated, the majority had squamous cell carcinomas; 89.4%, 89.8%, and 92.8% in 
Lusaka, Southern, and Western province, respectively. The rest of the cases were 
adenocarcinomas or the histology was not clearly specified.
Figure 2 shows age-specific incidence rates among the study population. The majority of 
cases occurred after age 40. The highest age-specific rates were observed in Lusaka 
followed by Southern and Western provinces.
Table 3 shows crude and adjusted cervical cancer rates for reproductive age 15 – 49 by 
province for the period 2007-2011. The crude and adjusted cervical cancer rates in Lusaka 
were about 2 to 4 times higher than the rates in the other 2 provinces. Table 4 shows the 
observed and expected incidence rates of cervical cancer in the reproductive age 15 – 49 for 
Southern and Western provinces based on observed incidence rates for Lusaka. Assuming 
that the Southern and Western provinces had similar risk factors to Lusaka province and 
adjusting for HIV prevalence, observed cervical cancer incidences in Southern province and 
Western province were underestimated by about 55% and 69%, respectively.
DISCUSSION
This study identified 5 interesting observations. First, the highest total and age-specific 
incidence rates of cervical cancer were found in Lusaka province followed by Southern 
province. The rates found in this study were higher than the IARC Globocan estimates for 
Zambia and Zimbabwe but similar to estimates for Malawi (1). The higher rate estimates 
could be due to higher HIV rate in Lusaka compared to the rest of the countries of the 
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Globocan projections (15). Furthermore, not until recently, Lusaka had higher HIV rates 
than Harare, Zimbabwe, which could be the reason for higher cervical cancer incidence in 
Lusaka (15). The HIV profile in Malawi is somewhat similar to that of Lusaka and that may 
have reflected on the similar cervical cancer rates in the 2 countries (15-18).
Second, we found that a little over 1/3 of cervical cancer patients were HIV-positive. Lusaka 
province has an HIV rate of 20.8 %, Southern province 14.5%, and Western province 15.2% 
(15). However, there was a significantly higher HIV seroprevalence among cervical cancer 
patients than the HIV seroprevalence in the general population of each respective province. 
The HIV seroprevalence in patients from Western province was 93% greater, Southern 
province 62% greater, and Lusaka province 46% greater than the general population. We 
also observed that patients in Western and Southern province were more frequently 
diagnosed with advanced stage cervical cancer (FIGO stage III/IV; Western = 60%, 
Southern = 57%, Lusaka = 49%). These observed differences may be associated with 
disparities in access and availability of diagnostic and treatment services as well as 
socioeconomic factors between the 3 provinces. Poverty prevalence in Lusaka province is 
24.4%, Southern province 67.9%, and in the Western province 80.4% (19). It is important to 
note that the majority of cases seen in Lusaka, Southern, and Western provinces were from 
the Cancer Diseases Hospital (CDH) and the University Teaching Hospital (UTH).
Third, we found a significant under-reporting of cervical cancer incidence in Southern and 
Western provinces. The under-reporting could be due to a lack of cancer registration in the 
provinces and/or the lack of or incomplete documentation of diagnosis in medical records. 
Furthermore, it is possible that patients die without being diagnosed with cervical cancer or 
reported as a case. The limited documentation of mortality makes it difficult to assess the 
magnitude of cervical cancer in peripheral regions in Zambia.
It is possible that some patients from different provinces in Zambia may report addresses of 
relatives/friends who reside in Lusaka. While the patients are asked about their permanent 
and temporary address during their first visit to the hospital in Lusaka, it cannot be 
confirmed that all patients report their actual permanent addresses. Among the factors that 
may contribute to this inflation is reporting by relatives or friends on behalf of the patients 
or lack of patient appreciation of the importance of the permanent address. There is no 
immediate method to account for this possibility but it should be considered and further 
explored in future studies.
Furthermore, 52% of patients from Lusaka, 40% of patients from the Southern province, and 
35% of patients from the Western province had unknown treatment information reported in 
the medical records. The high proportion of patients with unknown treatment could be 
attributed to incomplete documentation of treatment information, lack of record linkage and 
data integration systems, and perhaps lack of treatment. Whereas chemotherapy and 
radiotherapy treatment is offered free of charge at the CDH, the indirect expenses associated 
with treatment are unaffordable by most patients and could be a barrier in receiving or 
completing free treatment. Indirect costs and expenses that patients are required to provide 
include laboratory fees for investigations (approximately $200), if needed. In addition 
patients from outside Lusaka must pay for transportation and food expenses for themselves 
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and accompanying relatives who are required to nurse them especially in advanced. Studies 
in limited-resource settings have shown that financial expenses for cancer care beyond the 
cost of medications, surgery, and related treatment are significant barriers to availing cancer 
treatment. Out-of-pocket expenses for transportation, food, and lost income have been 
shown to inhibit and reduce patients’ willingness to start treatment for chronic illnesses 
(20-23).
The shortage in clinics, health professionals, and awareness about cervical cancer and its 
early detection, diagnosis, and treatment are more prominent in the 2 provinces included in 
this study than in Lusaka. For example, Lusaka has 6 hospitals compared to 2 hospitals in 
the Southern province, and none in the Western province. Also, Lusaka has significantly 
higher concentration of health care workers than the Southern and Western Provinces (24).
Fourth, when comparing whether patients received curative or palliative treatment, more 
proportions of patients from Southern and Western provinces had curative treatment than 
patients from Lusaka. This may have been due to the fact that beside under-documentation 
of treatment information, patients from distant locations who needed palliative treatment did 
not see a reason for paying for expenses of travel to the CDH for terminal conditions. A 
significant proportion of cervical cancer patients referred from these hospitals fail to make it 
to UTH or CDH. Failure of referral is usually due to patients’ preferences of seeking 
palliative care or management by local traditional healers and lack of financial resources for 
transportation and accommodation in Lusaka.
Fifth, the UTH Pathology results showed no evidence of malignancy in approximately 50% 
of tissue specimens suspected of cervical cancer. This may be due to high rate of referrals of 
early detection cases in Zambia or limited clinical skills and experience of primary care 
professionals who refer cases of infections as suspected cancers. Processing and examining 
half the workload of the main pathology department of the country for non-malignant 
lesions lead to long wait time for processing malignant lesions and delaying treatment of 
cervical cancer patients in the country.
As highlighted in the Introduction section, Zambia has made significant emphasis and 
achievements for the diagnosis of cervical cancer since 2006 through establishments of 
screening sites. Zambia also has succeeded in reducing the HIV infection rate, a major factor 
in increasing cervical cancer risk. The United Nations World AIDS’ Day report for 2012 
emphasized that the rate of new HIV infections in Zamia has declined between 2001 and 
2011 by 68% and 80% of HIV patients received treatment (25). Zambia has established the 
first cancer center in Lusaka and more efforts are needed for treating cancer patients and 
emphasizing patient, public, and professional cancer education efforts.
In conclusion, this study demonstrated the burden, late stage, and underestimation of 
cervical cancer in 3 Zambian provinces. The study also highlighted the importance of HIV 
in cervical cancer pathogenesis and the challenges encountered in diagnosis and case 
ascertainment in Zambia and possibly other similar low-income countries. With increasing 
screening facilities in Zambia and longer survival for HIV patients who receive anti-
retroviral treatment, the incidence of cervical cancer is likely to increase. Therefore, future 
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studies should place more emphasis on educating primary care professionals about the 
differential diagnosis of cervical cancer, better documentation of diagnosis and treatment of 
cervical cancer, improving patient access to treatment, and enhancing the quality of cancer 
registries in Zambia and other similar low-income countries.
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Figure 1. 
Summary of Collected Data
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Figure 2. 
Age-specific incidence rates of cervical cancer in Lusaka, Southern, and Western provinces 
of Zambia (per 100,000)
Kalima et al. Page 11
Int J Gynecol Cancer. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Kalima et al. Page 12
Table 1
Demographic characteristics of cervical cancer patients seen at the study hospitals
Variable Lusaka Southern Western P-value
Total No. of Cases 2407 760 315
Age in Years2364,743,306
Mean 46.3 50.0 49.1
< 0.0011
Median 43 48 47
Std. Deviation 15.04 14.96 14.81
Range (Min, Max) 80 (19,99) 78 (20,98) 81 (17,98)
Year of Diagnosis 2407,760,315 No. % No. % No. %
2007 306 12.7 83 10.9 41 13.0
< 0.0012
2008 381 15.8 95 12.5 45 14.3
2009 573 23.8 145 19.1 37 11.7
2010 625 26.0 138 18.2 44 14.0
2011 522 21.7 131 17.2 78 24.8
2012 - - 168 22.1 70 22.2
Source 2407,760,315
Cancer Diseases Hospital 639 26.5 256 33.7 92 29.2
University Teaching Hospital 386 16.0 103 13.6 1 0.3
Livingstone General Hospital 0 0.0 104 13.7 19 6.0
Lewanika General Hospital 0 0.0 0 0.0 95 30.2
Prospects Laboratory 47 2.0 1 0.1 0 0.0
National Cancer Registry3 1335 55.5 296 38.9 108 34.3
Marital Status 1902,528,201
Unmarried 455 23.9 141 26.7 67 33.3 0.012
Married 1447 76.1 387 73.3 134 66.7
Occupation 443,217,85
Unemployed Unmarried 108 24.4 38 17.5 24 28.2
< 0.0012
Unemployed Married 147 33.2 61 28.1 26 30.6
Farming / Agriculture 44 9.9 75 34.6 23 27.1
Business 66 14.9 14 6.5 8 9.4
Other 78 17.6 29 13.4 4 4.7
HIV Status 1785,489,184
Negative 1243 69.6 374 76.5 130 70.7 0.012
Positive 542 30.4 115 23.5 54 29.3
1ANOVA comparing Lusaka, Southern, and Western Province
2Chi-square comparing Lusaka, Southern, and Western Province
3National Cancer Registry Data was not available for 2012.Other superscript values represent total cases in each province for each variable.
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Table 2
Clinical characteristics of cervical cancer patients seen at the study hospitals
Variable Lusaka Southern Western P-value
Total number of cases 2407 760 315
FIGO Stage No. % No. % No. %
I 78 3.2 24 3.2 8 2.5 0.061
II 451 18.7 112 14.7 50 15.9
III 426 17.7 158 20.8 75 23.8
IV 87 3.6 25 3.3 13 4.1
Missing 1365 56.7 441 58.0 169 53.7
Treatment Status2
Radiotherapy & Chemotherapy 102 4.2 41 5.4 26 8.3
< 0.011
Radiotherapy Only 45 1.9 41 5.4 14 4.4
Radiotherapy, Unknown Chemotherapy 139 5.8 50 6.6 14 4.4
Unknown Treatment Status 2096 87.1 606 79.7 255 81.0
Not Received Treatment 25 1.0 22 2.9 6 1.9
Treatment Intent2
Palliative 75 3.1 29 3.8 9 2.9
< 0.011
Curative 145 6.0 94 12.4 42 13.3
Unknown (treatment status unknown /un-received) 2187 90.9 637 83.8 264 83.8
Histology
Squamous Cell Carcinoma 1985 82.5 526 69.2 167 53.0
< 0.011
Adenocarcinoma 125 5.2 46 6.1 4 1.3
Histopathology Cell Type not Specified 110 4.6 14 1.8 9 2.9
Missing 187 7.8 174 22.9 135 42.9
1Chi-square comparing Lusaka, Southern, and Western province
2
Data from CDH only
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Table 3
Crude and adjusted cervical cancer rates for reproductive age 15 – 49 by province for the period 2007-2011
PROVINCE
Lusaka Southern Western
Number 1534 310 127
Crude rate 54.1 17.1 12.3
ASR (W) 82.1 25.5 17.2
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Table 4
Expected incidence rates in Southern and Western based on Lusaka province observed incidence rates for the 
period 2007-2011
PROVINCE
Southern Western
Observed rate 17.1 12.3
Expected rate 37.9 39.5
Under-estimation 54.9% 69.0%
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